Clinical trial
AD 32 With or Without BCG After Surgery in Treating Patients With Newly…
NCT00003759 · Anthra Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00003759 |
|---|---|
| Title | AD 32 With or Without BCG After Surgery in Treating Patients With Newly Diagnosed or Recurrent Superficial Bladder Cancer |
| Official title | Intravesical Treatment of Superficial Bladder Cancer Characterized on the Basis of the Tumor Markers p53 and pRb |
| Lead sponsor | Anthra Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Bladder Cancer |
| Intervention type | Biological, Drug, Procedure |
| Interventions | BCG vaccine, valrubicin, conventional surgery |
| Start date | Nov 1, 1998 |
| Completion | Nov 1, 2002 |
| First posted | Jul 18, 2003 |
| Last update posted | Jan 31, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: